English (UK)
中文版Min Zhou
Hainan Haiyao, a Chinese public company with stock code of 000566, is established in 1965, mainly focused on some severe diseases such as infection, tumor, digestion system etc.
Hainan Haiyao Co. , Ltd
BD DirectorIvy Zhou
Shenzhen Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.
Shenzhen Beimei Pharmaceutical Co. Ltd.
Head of Business DevelopmentKaiqi Zhou
Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.
Shanghai MicroPort Medical
BD AssociateDr. John Zhu
Duality Biologics is a China biotech company focusing on the discovery, development and commercialization of new modality biologics to provide solutions to unmet medical needs for grievous diseases in Great China area. Backed by proprietary new modality platform ensuring fast biological validation and development, Duality Biologics has been building a combined pipeline of First-in-class and Best-in-class. Currently, Duality seeks for licensing-in opportunities in broad disease areas especially oncology and autoimmune diseases
Duality Biologics
Founder and CEOchuhan zong
A mainland based family fund， heavily investing healthcare and biotechs
Wu Capital
associateFangyue Zou
Founded in Wuxi, 2017
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China
Responsive Web Design powered by 